Group 1 - The Hong Kong innovative drug sector experienced a downward trend, with the Hong Kong Stock Connect Innovative Drug ETF (520880) dropping over 1% in early trading on February 26 [1] - Among the constituent stocks, Jiage Ankang-B led with a gain of over 5%, while Baiji Shenzhou fell sharply by 3% [1] - The industry is seeing active external licensing transactions, with Innovent Biologics and Eli Lilly forming a global strategic partnership focused on oncology and immunology [3] Group 2 - Key pipelines are making progress overseas, with two innovative drugs from CSPC Pharmaceutical Group starting Phase III clinical trials and receiving FDA IND approval [3] - Jianghai Securities predicts that by 2026, pharmaceutical business development (BD) transactions will focus on unmet clinical needs, technological differentiation, and globalization [3] - Huachuang Securities emphasizes the transition in the innovative drug industry from quantity to quality, suggesting a focus on differentiated domestic and international pipelines by 2025 [3] Group 3 - The Hong Kong Stock Connect Innovative Drug ETF (520880) passively tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, with top ten weighted stocks including CSPC Pharmaceutical Group and Baiji Shenzhou [3]

本报记者 曹卫新 2026年，中国创新药对外BD交易（商务拓展交易）持续升温、势头强劲。医药魔方NextPharma数据库显示，截至2月25 日，年内中国创新药已发生44起对外授权（license-out）交易事件，首付款约为31.23亿美元，总金额达532.76亿美元。 普华永道中国医药医疗行业主管合伙人徐佳博士在接受《证券日报》记者采访时表示："近期中国创新药海外授权 （License-out）交易密集落地，折射出中国创新药产业正从'跟跑'向'并跑'乃至'领跑'转变，实现了从'引进模仿'向'创新输出'的 结构性跨越。这不仅标志着中国正成为全球不可或缺的创新策源地，也意味着中国在全球医药创新价值链中的话语权和影响力 持续增强。" 跨境BD交易密集落地 医药魔方NextPharma数据库显示，2025年，中国创新药BD"出海"授权全年交易总金额达到1356.55亿美元，首付款70亿美 元，交易总数量达到157起，各个维度的数据统计均创历史新高。 进入2026年，中国创新药对外BD交易势头不减。1月16日，西比曼生物科技（一家处于临床阶段的专注于创新细胞疗法发 现和开发的全球性生物制药公司）宣布与阿斯利康达成协 ...

Market Performance - The Hong Kong stock market showed mixed performance with the Hang Seng Index rising by 0.66% to 26,765.72 points, while the Hang Seng Tech Index fell by 0.19% to 5,260.5 points [1] - Major technology stocks had varied movements, with Alibaba up 0.2%, Tencent up 0.48%, and Meituan up 1.6%, while Xiaomi and NetEase saw declines of 0.39% and 0.61% respectively [1] Sector Highlights - The steel, non-ferrous metals, and rare earth sectors led the gains, with Chongqing Steel rising nearly 8% and China Aluminum up 5% [1] - The semiconductor sector weakened, with Lattice Semiconductor down over 7% [1] - The AI application sector experienced a pullback, with Zhiyun down 10.75% [1] Company-Specific Movements - Sinochem Fertilizer saw a rise of over 3% due to international phosphate prices exceeding $700 per ton [2] - Dongyue Group increased by nearly 7% supported by low refrigerant inventory and bullish price expectations [3] - Dazhu CNC rose over 5% after its laser drilling machine received certification from NVIDIA [4] - Huizhu Technology surged over 10%, reaching a historical high after raising HKD 1.635 billion [5] - Hongteng Precision increased over 6% as it transitions towards high-margin AI server interconnect and electric vehicle businesses [6] - Mingming Henan saw a rise of nearly 9% as its leading position in the industry was reaffirmed [8] Analyst Insights - Analysts from China Galaxy Securities highlighted three main themes for the Hong Kong market: rising geopolitical risks boosting precious metals, consumer policy driving low-valuation consumer stock recovery, and the release of valuation pressure in the tech sector [12] - Haitong International expressed optimism about the pharmaceutical sector, particularly Stone Pharmaceutical Group, expecting it to return to an upward cycle by 2026 [12]

Group 1: Market Performance - The A-share biopharmaceutical ETF Huatai Fuhua (159839) rose by 1.1%, with a total trading volume exceeding 22 million yuan, marking the fourth consecutive day of inflows totaling over 20 million yuan [2] - The Hong Kong biopharmaceutical ETF Huatai Fuhua (513280) fluctuated and closed flat, with a trading volume exceeding 42 million yuan, and a net inflow of over 17 million yuan in the last 60 days [3] - The majority of the popular component stocks in the biopharmaceutical ETF Huatai Fuhua (159839) showed positive performance, with Changchun High-tech hitting the daily limit and its subsidiary GenSci141 ointment receiving clinical trial approval [5] Group 2: Company Performance - WuXi AppTec (药明康德) reported a significant performance increase, with a projected net profit growth of 41.3% in 2025, driven by the TIDES business, which saw revenue growth exceeding 90% [8] - WuXi Biologics (药明生物) achieved a record total of 945 projects, with a 30% growth in dual monoclonal antibodies and ADC projects, indicating strong future revenue potential [8] - The domestic clinical CRO market is expected to return to a growth trajectory in 2025, benefiting companies like Tigermed (泰格医药) from improved order prices and increased clinical pipeline numbers [8] Group 3: Industry Trends - The global CXO industry is expected to continue its strong recovery, with significant investment and transaction demand in the biotech and pharmaceutical sectors anticipated to rebound in 2025 [7] - The Chinese innovative drug market is showing robust activity, with a 19% year-on-year increase in IND numbers and a substantial rise in BD transaction amounts, indicating a vibrant domestic market [7] - The Chinese innovative drug sector is transitioning from pipeline expectations to revenue realization, with over 70% of companies projected to achieve positive revenue growth in 2025 [11]

CagriSema曾被寄予厚望，诺和诺德将其定位为比司美格鲁肽更强效的继任者，且诺和诺德未来60%的 增长将来自于CagriSema。最新头对头数据的公布也意味着这一希望可能破灭。不过，诺和诺德称，计 划于今年下半年进行更高剂量的临床试验。 消息面上，诺和诺德新一代减重药CagriSema头对头比较礼来减重药替尔泊肽（Tirzepatide）的三期临床 试验结果显示，在84周内，CagriSema实现减重23%，疗效不及礼来替尔泊肽25.5%的减重效果。 股价受累 2月24日，据业内消息，诺和诺德宣布，自2027年1月1日起，旗下减重明星药（司美格鲁肽）在美国市 场的标价将下调50%，月费降至675美元。 在2月23日，欧洲股市开盘后，诺和诺德股价直线跳水，盘中一度暴跌超15%，创下2021年6月以来最低 水平。截至2月24日收盘，其股价为38.59美元/股，跌幅2.62%，总市值为1716亿美元。 新品研发不及预期，直接影响了诺和诺德股价。2024年6月，诺和诺德市值一度攀升至6500亿美元的历 史高点，成为欧洲市值最高的上市公司。当时，其市值不仅超越了德国软件巨头SAP，也超过了 LVMH、ASML等欧洲 ...

作者 |第一财经 钱童心 2月25日亚太股市开盘后，联邦制药（3933.HK）股价一路上涨，下午股价一度飙涨超过7%。 前一日，联邦制药公布了新一代三重靶点减重药UBT251中国的一项中期临床试验数据，该注射液每周 给药一次，在连续给药24周后，试验药组平均减重达19.7%，安慰剂组仅为2%。 2026.02.25 本文字数：1021，阅读时长大约2分钟 在减重药竞争日益加剧的背景下，跨国制药巨头纷纷聚焦中国的减重药资产。就在2月24日，中国减重 药开发商先为达生物宣布与辉瑞中国达成战略合作，辉瑞将获得其核心GLP-1类产品埃诺格鲁肽注射液 在中国大陆的独家商业化权益。这项合作总交易额最高可达近5亿美元。 去年12月，辉瑞还与复星医药控股子公司药友制药达成许可协议，获得一款口服小分子GLP-1受体激动 剂的全球独家权益，交易总额超过20亿美元。 去年7月，石药集团以20.75亿美元将口服小分子GLP-1受体激动剂授权给Madrigal公司；今年年初，石 药集团又将另一款双靶点的新一代减重注射药授权给阿斯利康。 目前，包括恒瑞医药、翰森制药、诚益生物在内的本土药企的GLP-1类药物都已经通过对外授权的方式 实现 ...

Core Viewpoint - The competition in the weight loss drug market is intensifying, prompting multinational pharmaceutical companies to focus on weight loss drug assets in China [1][5]. Group 1: UBT251 Clinical Trial Results - Federal Pharmaceuticals' stock surged over 7% following the announcement of mid-term clinical trial data for its new generation triple-target weight loss drug UBT251, which showed an average weight loss of 19.7% in the treatment group after 24 weeks, compared to only 2% in the placebo group [1][4]. - An endocrinology expert commented that the trial results are "very good," highlighting the potential of new generation weight loss drugs developed in China [4]. Group 2: Strategic Partnerships and Market Potential - In March of last year, Novo Nordisk entered into a licensing agreement with Federal Pharmaceuticals for UBT251, with an upfront payment of $200 million and a potential total deal value of up to $2 billion [4]. - The global market for GLP-1 drugs is projected to reach $95 billion by 2030 and could expand to $120 billion by 2035, according to a report from Goldman Sachs [5]. Group 3: Other Collaborations in the Market - On February 24, Chinese weight loss drug developer Xianweida Biotech announced a strategic partnership with Pfizer China, granting Pfizer exclusive commercialization rights for its core GLP-1 product, with a total deal value potentially reaching nearly $500 million [2][5]. - In December, Pfizer also secured a licensing agreement with a subsidiary of Fosun Pharma for a global exclusive right to an oral small molecule GLP-1 receptor agonist, with a deal value exceeding $2 billion [5].

在减重药竞争日益加剧的背景下，跨国制药巨头纷纷聚焦中国的减重药资产。 2月25日亚太股市开盘后，联邦制药（3933.HK）股价一路上涨，下午股价一度飙涨超过7%。 值得关注的是，去年3月，诺和诺德与联邦制药就UBT251达成了授权协议，首付款2亿美元，潜在交易 总额高达20亿美元。 UBT251是一款在研的针对GLP-1/GIP/GCG三重靶点的新一代减重药，有望较目前礼来的双靶点GLP-1 减重药获得更好的减重效果。 去年7月，石药集团以20.75亿美元将口服小分子GLP-1受体激动剂授权给Madrigal公司；今年年初，石 药集团又将另一款双靶点的新一代减重注射药授权给阿斯利康。 目前，包括恒瑞医药、翰森制药、诚益生物在内的本土药企的GLP-1类药物都已经通过对外授权的方式 实现出海。 前一日，联邦制药公布了新一代三重靶点减重药UBT251中国的一项中期临床试验数据，该注射液每周 给药一次，在连续给药24周后，试验药组平均减重达19.7%，安慰剂组仅为2%。 一位未参与临床试验的内分泌专家对第一财经记者表示，这一试验结果"非常不错"，展示了中国研发的 新一代减重药的潜力。 这一积极的临床数据也为急需利好消 ...

Investment Rating - The industry investment rating is maintained at "Overweight" [7] Core Insights - The report highlights the continuous upgrading of policies in the Heilongjiang biomanufacturing industry, focusing on innovative traditional Chinese medicine and innovative medical devices [4] - The report emphasizes the significant revisions to the Drug Administration Law, which provides institutional support for pharmaceutical innovation and high-quality development [4] - The report identifies three major transformations in China's innovative drug business development (BD) in 2026: technology output combined with product authorization, platform cooperation, and global parallel innovation [8] Summary by Sections Industry Performance - Over the past 12 months, the industry has shown a relative return of -7.06% compared to the CSI 300 index, with an absolute return of 11.53% [3] Investment Highlights - The report notes that BD transactions in the pharmaceutical sector are focused on unmet clinical needs, technological differentiation, and global value [6] - Key areas of focus include oncology therapies such as dual antibodies, ADCs, and TCE combinations, with significant financial agreements highlighted, such as a $650 million upfront payment for a PD-1/VEGF dual antibody [6] - The metabolic disease sector is centered on long-acting GLP-1 and small nucleic acid precision therapies, with notable collaborations resulting in substantial upfront payments and potential total amounts [6] Company-Specific Developments - Companies like Andover Pharmaceuticals and Frontier Biotech have secured significant collaborations with major pharmaceutical firms, indicating a trend towards platform-based cooperation and technology output [7] - Specific collaborations include a $1.05 billion deal for a CTLA-4 inhibitor and a $400 million agreement for small nucleic acid drugs, showcasing the growing interest in innovative therapies [7] - The report suggests monitoring companies such as Rebio Biotech and WuXi AppTec for their advancements in small nucleic acids and platform capabilities [8]

Core Viewpoint - Haitong International reports that the main business revenue and profit of CSPC Pharmaceutical Group (01093) have bottomed out, with expectations to return to an upward cycle by 2026 and benefit from the launch of innovative oncology and metabolic products starting in 2027 [1] Group 1: Revenue and Profit Outlook - The potential milestone revenue for CSPC Pharmaceutical Group is estimated at $5.8 billion (approximately RMB 40.6 billion), which is expected to gradually enhance the company's profits over the next 3-5 years [1] - The firm believes that upfront payments and milestone revenues will provide sustainable recurring income for the company, leading to an upward revision of the revenue forecast for authorized products post-2027 [1] Group 2: R&D and Collaboration - CSPC Pharmaceutical Group has achieved seven external collaboration deals in the past two years, with total upfront payments of $1.71 billion and potential milestone revenues exceeding $30 billion [2] - The company has partnered with AstraZeneca three times, highlighting its R&D platform's global influence and value [2] - The firm is optimistic about CSPC's ability to generate regular income through milestone sales and net revenue sharing throughout the drug lifecycle [2] Group 3: Pipeline and Technology - CSPC's small nucleic acid platform has a broad layout, targeting popular liver delivery points such as PCSK9, AGT, and ANGPTL3, and is ahead of domestic peers in development [3] - The company has applied for patents related to lipid delivery and specific siRNA treatments, indicating potential advancements in neurological and ocular delivery technologies [3] - The SYS6010 (EGFR-ADC) has accumulated clinical data from over a thousand patients, showing potential for best-in-class efficacy and safety [4] Group 4: Clinical Developments - The company has initiated a Phase III clinical trial for SYS6010 in China for first-line treatment of non-small cell lung cancer (NSCLC) and plans to advance global Phase III trials [4] - CSPC's in vivo CAR-T product, SYS6055, has received clinical approval in China, representing the first in vivo CAR-T product approved domestically, with potential advantages in cost and accessibility [4] Group 5: Financial Projections - The firm has adjusted revenue forecasts for FY25, FY26, and FY27 to RMB 26.7 billion, 28.9 billion, and 30.6 billion respectively, reflecting changes in the recognition of upfront payments [5] - The net profit forecasts for FY25, FY26, and FY27 have been revised to RMB 4.4 billion, 4.6 billion, and 5.3 billion respectively [6]